Aquestive Therapeutics, Inc. (AQST)
| Market Cap | 172.27M |
| Revenue (ttm) | 41.88M |
| Net Income (ttm) | -63.96M |
| Shares Out | 38.89M |
| EPS (ttm) | -1.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 298,887 |
| Open | 4.18 |
| Previous Close | 4.22 |
| Day's Range | 4.17 - 4.43 |
| 52-Week Range | 3.10 - 8.60 |
| Beta | 3.61 |
| Analysts | Buy |
| Price Target | 15.20 (+243.1%) |
| Est. Earnings Date | Nov 2, 2021 |
About AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with...
Financial Performance
In 2020, AQST's revenue was $45.85 million, a decrease of -12.85% compared to the previous year's $52.61 million. Losses were -$55.78 million, -15.79% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 15.20, which is an increase of 243.12% from the latest price.
News
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year R...
WARREN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...
Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Stocks To Watch With The Stock Market Down Today
Which Penny Stocks Are Investors Watching After the Stock Market Crash? The post 4 Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | P...
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) ...
WARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
WARREN, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer
WARREN, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences
WARREN, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...
Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patien...
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
WARREN, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patient...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. an...
Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...
AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Actio...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "th...
AQST Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages Aquestive Therapeutics, Inc. Investors w...
New York, New York--(Newsfile Corp. - April 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...
AQST IMPORTANT DEADLINE FRIDAY: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Los...
NEW YORK, April 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2...
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc....
Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...
APRIL 30, 2021 AQST INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaint...
New York, New York--(Newsfile Corp. - April 29, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securi...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such i...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive ...
LOS ANGELES--(BUSINESS WIRE)---- $AQST #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics,...
Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...
AQST Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Ac...
New York, New York--(Newsfile Corp. - April 28, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive"...
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutic...
Los Angeles, California--(Newsfile Corp. - April 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...
Rosen, Top Ranked Global Investor Counsel, Encourages Aquestive Therapeutics, Inc. Investors with Losses Over $100K t...
New York, New York--(Newsfile Corp. - April 25, 2021) - WHY: New York, N.Y., April 25, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeu...
Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Hos...
WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pati...